drugset / Trial / NCT06687941
A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
Phase 1
Recruiting
70 enrolled
Aptamer Sciences, Inc.
CHA University · collabNational Cancer Center, Korea · collabSamsung Medical Center · collabSeverance Hospital · collab
NaSequentialOpen-labelTreatment
Summary
This is the first in human trial clinical study of AST-201 in patients with GPC3-positive advanced solid tumors. This study aims to evaluate the safety, tolerability, pharmacokinetic properties, and preliminary efficacy of AST-201 across various tumor types.
Timeline
- Start
- 2025-03-11
- Primary completion
- 2027-12
- Completion
- 2028-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AST-201 | Vaccine | — | Intravenous |